preloader

The Iranian Cancer Research Center joins BIG

Intro text: 

 

The Iranian Cancer Research Center (ICRC) joined BIG during the organisation’s General Assembly that took place on 31 May 2015. 
Dr. Sanaz Tabarestani, Cancer Genetics Director of ICRC and BIG voting representative, tells us about the group’s history and current research and introduces us to the Iranian breast cancer research scenario.

Could you please give a brief description of your group?

The Iranian Cancer Research Center (ICRC) is a well-known comprehensive cancer center located at Tajrish Shohada Hospital in Tehran, Iran. It was established in 2005, at one of the academic hospitals of Shahid Beheshti University of Medical Sciences. The chairman of ICRC is Professor Mohammad Esmaeil Akbari, who is a professor of surgical oncology. Around 5000 breast cancer patients and 600 new breast cancer patients are managed annually at ICRC.Currently, three hospitals are affiliated with ICRC, including Tajrish Shohada Hospital, Khatam Hospital, and Azar Center. We usually hold three international cancer conferences each year, one of which is dedicated exclusively to breast cancer. Our 11th international breast cancer conference will take place in February 2016. Since 2008, we have been publishing the “Iranian Journal of Cancer Prevention”, which is considered a very important cancer journal in Iran.

Why did your group join the BIG network and how do you hope to benefit from this affiliation?

At ICRC, we believe that inter-sectoral collaboration, data integration and comprehensive activities are three important elements of development. We joined BIG to collaborate with other research groups, to integrate our data, and to provide patients with more comprehensive care.  

What are the biggest challenges faced by your group in the scientific and research area?

Basic science research in our region is poorly developed, so we cannot rely much on our own data. Furthermore, inter-sectoral collaboration within our country and international collaboration are challenging.

'We need international research collaboration to run joint projects in breast cancer that will take into account the specific interests of each research group involved, with the ultimate goal of improving patient management and care.'


What are the objectives of your group for your own region?

Our main objective is to perform applied research in order to develop clinical guidelines for the better management of breast cancer patients.

What does international research collaboration mean for you?

We need international research collaboration to run joint projects in breast cancer that will take into account the specific interests of each research group involved, with the ultimate goal of improving patient management and care.

How are clinical trials conducted and managed under your group's leadership?

We usually conduct two clinical trials per year. All clinical trials are performed and managed under the direct supervision of ICRC’s chairman, Professor Akbari, who is also head of the clinical trials section.

What have been, in your opinion, your group's biggest achievements or toughest challenges so far?

Our main goal and challenge is to provide national guidelines for the management of breast cancer patients.

 

Read more about ICRC, its mission and clinical projects on their website